SVB Leerink raised the price target for the AbbVie Inc. (NYSE:ABBV) stock to ‘an Underperform’. The rating was released on May 23, 2023, according to finviz. The research report from Morgan Stanley has resumed the stock to Overweight, with a price target set at $192. The stock was downgraded by UBS, who disclosed in a research note on February 28, 2023, from Buy to Neutral and set the price objective to $147. In their research brief published February 03, 2023, Goldman analysts reiterated the AbbVie Inc.
What does AbbVie Inc. (ABBV) Stock have to offer?
